COCP · Cocrystal Pharma, Inc.

Summary

Operating Income was -$9.0M (49.6%) Net Income was -$8.8M (49.5%) Eps was $-0.78 (54.7%) Free Cash Flow was -$8.2M

Key takeaways

• Operating loss narrowed 49.6% to -$9.0M, primarily driven by the winding down of clinical study costs for drug candidates and reductions in employee-related expenses.
• Net loss improved 49.5% to -$8.8M, reflecting reduced clinical trial activity and lower general administrative expenses including insurance and compensation.
• Diluted EPS improved 55% to -$0.78, benefiting from the reduced net loss despite an increased share count from equity raises.
• Net cash used in operating activities decreased 50% to -$8.2M, compared to -$16.5M in the prior year, aligning cash consumption with the reduced operational scope.
• The company continues to incur losses and acknowledges that achieving profitability is dependent on successful development and commercialization of product candidates.